1.) Considered and approved Un-audited financial results for the quarter and nine months ended on 31st December 2024. 2.) The board has considered and approved the appointment of Mr. Kelash Bunkar as Whole-time Director and Chief Financial Officer of the Company w.e.f 05.02.2025. 3.) The board has considered and accepted the resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer of the Company w.e. f 05.02.2025 4.) Mr. Aman Patel is appointed as non-executive independent director of the company w .e. f. 05.02.2025 subject to approval of members. 5.) The board has considered and accepted the of Independent Director Ms Komal Chauhan w e.f 05.02.2025. The board meeting commenced at 03:30 PM and concluded at 04:25 PM

pdf

Biogen Pharmachem Industries Ltd.

22 Jan 2025

0.83

-2.35%

Board Meeting

Biogen Pharmachem Industries Ltd - 531752 - Board Meeting Intimation for Compliance Of Regulation 29 Of …

BSE India

Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 5th February 2025 inter alia, to consider following business. - 1.) To approve and take on record the Un-Audited Financia l Results of the Company for the quarter ended on 31''t December 2024. 2.) To approve and consider the appointment of Mr. Kelash Bunkar as Whole time Director and Chief Financial Officer of the Company. 3.) To consider the resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer of the Company. 4.)To approve and consider the appointment of Mr. Aman Patel as Director of the Company. 5.) To consider the resignation of Ms. Komal Chauhan from directorship of the Company. 6.) Any other matter with the permission of the board which the Board may think fit. Thanking You.

pdf

Biogen Pharmachem Industries Ltd.

17 Jan 2025

0.83

-2.35%

Corp. Note

Biogen Pharmachem Industries Ltd - 531752 - Board Meeting Outcome for Outcome Of Board Meeting Held …

BSE India

We wish to inform that the Board of Directors in their meeting held today, i.e., January 17 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 40% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 05:00 P.M. and concluded at 05:30 P.M. This is for your information. Thanking You.

pdf

Biogen Pharmachem Industries Ltd.

11 Jan 2025

0.83

-2.35%

Company Update

Biogen Pharmachem Industries Ltd - 531752 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

PFA

pdf

Biogen Pharmachem Industries Ltd.

27 Dec 2024

0.83

-2.35%

SAST

Biogen Pharmachem Industries Ltd - 531752 - Closure of Trading Window

BSE India

PFA

pdf

Biogen Pharmachem Industries Ltd.

29 Nov 2024

0.83

-2.35%

Corp. Note

Biogen Pharmachem Industries Ltd - 531752 - Board Meeting Outcome for Outcome Of Board Meeting Held …

BSE India

We wish to inform that the Board of Directors in their meeting held today, i.e., 29th November 2024, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty eight paise) each upon receipt of 25% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 5:30 P.M. and concluded at 06:00 P.M. This is for your information Thanking You.

pdf

Biogen Pharmachem Industries Ltd.

13 Nov 2024

0.83

-2.35%

Result

Biogen Pharmachem Industries Ltd - 531752 - Un-Audited Financial Result Quarter And Half Year Ended On …

BSE India

PFA

pdf

Biogen Pharmachem Industries Ltd.

13 Nov 2024

0.83

-2.35%

Board Meeting

Biogen Pharmachem Industries Ltd - 531752 - Board Meeting Outcome for Un-Audited Financial Result Quarter And …

BSE India

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of t he SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Wednesday 13th November 2024 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th September, 2024. The meeting commenced at 05.30 P.M. and concluded at 06.00 P.M. Kindly take the same on your record and oblige. Thanking You.

pdf

Is Sun Techno Overseas Ltd. worth buying?

101 Votes:

Buy 74.26%

Sell 10.89%

Hold 14.85%